Puma Biotechnology

217 articles with Puma Biotechnology

• Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) on December 11, 2018

  12/11/2018

  Puma Biotechnology, Inc. announced that in connection with the appointment of Maximo F. Nougues as Puma’s Chief Financial Officer, the Compensation Committee of Puma’s Board of Directors approved a grant to Mr. Nougues of an inducement stock option to purchase 90,000 shares of Puma common stock, at an exercise price per share equal to the closing price of Puma’s common stock on the grant date.

• Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) on December 10, 2018

  12/10/2018

  Puma Biotechnology, Inc. announced that in connection with the appointment of Maximo F. Nougues as Puma’s Chief Financial Officer, the Compensation Committee of Puma’s Board of Directors approved a grant to Mr. Nougues of an inducement stock option to purchase 90,000 shares of Puma common stock, at an exercise price per share equal to the closing price of Puma’s common stock on the grant date.

• Puma Biotechnology Presents Results from the Hormone Receptor Positive Subgroup in Phase III ExteNET Trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium

  12/6/2018

  Puma Biotechnology, Inc. announced that results from the subgroup of patients with hormone receptor positive (HR-positive) breast cancer from the Company’s Phase III ExteNET Trial of neratinib for early stage HER2-Amplified breast cancer are being presented at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas.

• Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium

  12/6/2018

  Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, is presenting updated results from a Phase II clinical trial of Puma’s drug neratinib at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas.

• Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio Breast Cancer Symposium

  12/6/2018

  Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's drug neratinib are being presented at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas

• uBiome Announces First Stage of CDx Development in Collaboration w/ Puma Biotechnology

  12/5/2018

  Today announced the first stage of companion diagnostic development with Puma Biotechnology to investigate the role of the microbiome in adverse events related to neratinib treatment of patients with HER2-positive breast cancer. 

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) on December 2, 2018

  12/3/2018

  Puma Biotechnology, Inc. announced that on December 2, 2018 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 44,875 shares of Puma common stock to 10 new non-executive employees.

• 

  Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years

  11/19/2018

  According to the American Cancer Society, almost 601,000 people in the U.S. died of cancer in 2017. The two most common types of cancer are lung cancer and breast cancer, followed by colorectal cancer, prostate cancer and stomach cancer. 

• Puma Biotechnology to Present at the 27th Credit Suisse Healthcare Conference

  11/7/2018

  Puma Biotechnology, Inc. announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 9:10 a.m. MST (8:10 a.m. PST, 11:10 a.m. EST) on Wednesday, November 14, at the Credit Suisse 27th Annual Healthcare Conference.

• Puma Biotechnology Reports Third Quarter 2018 Financial Results

  11/1/2018

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2018

• Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2018 Financial Results

  10/18/2018

  Puma Biotechnology, Inc. will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, November 1, 2018 following release of its third quarter 2018 financial results.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) on October 9, 2018

  10/10/2018

  Puma Biotechnology, Inc. announced that on October 9, 2018, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 18,750 shares of Puma common stock to two new non-executive employees.

• Puma Biotechnology’s Licensing Partner CANbridge Pharmaceutical Submits New Drug Application for NERLYNX® (neratinib) in China

  10/2/2018

  NERLYNX was approved in the United States for the same indication in July 2017 and in the European Union for the extended adjuvant treatment of hormone receptor-positive HER2-positive early stage breast cancer in September 2018.

• Puma Biotechnology to Present at 2018 Cantor Global Healthcare Conference

  9/20/2018

  Puma Biotechnology, Inc. announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 1:10 p.m. EDT on Monday, October 1, at the Cantor Global Healthcare Conference.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) on September 5, 2018

  9/6/2018

  Puma Biotechnology, Inc. announced that on September 5, 2018 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 31,125 shares of Puma common stock to four new non-executive employees.

• CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China

  8/14/2018

  CANbridge Life Sciences, a biopharmaceutical company developing Western drug candidates in China and North Asia, announced that the China National Drug Administration (CNDA) has approved the Investigational New Drug (IND) application for a Phase Ib/III clinical study of CAN017 in esophageal squamous cell cancer (ESCC).

• Puma Biotechnology Reports Second Quarter 2018 Financial Results

  8/9/2018

  Puma Biotechnology, Inc. announced financial results for the second quarter ended June 30, 2018.

• Puma Biotechnology Files New Drug Submission for NERLYNX® in Canada

  7/31/2018

  Puma Biotechnology, Inc. announced that Health Canada has accepted for review the Company’s New Drug Submission (NDS) for the medicinal product NERLYNX® (neratinib) for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy.

• Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results

  7/26/2018

  Puma Biotechnology, Inc. will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 9, 2018 following release of its second quarter 2018 financial results.

• Puma Biotechnology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Neratinib HER2 Mutation Basket Study (SUMMIT Trial)

  7/17/2018

  Puma Biotechnology, Inc. and Strata Oncology, Inc. have entered into a collaborative agreement to accelerate patient enrollment in Puma’s ongoing Phase II SUMMIT trial of PB272 (neratinib).